Insider Buying: Bausch Health Companies Inc. (NYSE:BHC) Director Buys 3,564,059 Shares of Stock

Bausch Health Companies Inc. (NYSE:BHC - Get Free Report) Director John Paulson bought 3,564,059 shares of the company's stock in a transaction dated Friday, June 13th. The stock was purchased at an average cost of $5.94 per share, for a total transaction of $21,170,510.46. Following the completion of the acquisition, the director now owns 32,791,702 shares in the company, valued at $194,782,709.88. This trade represents a 12.19% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

John Paulson also recently made the following trade(s):

• On Thursday, June 12th, John Paulson purchased 1,005,376 shares of Bausch Health Companies stock. The shares were acquired at an average price of $5.47 per share, with a total value of $5,499,406.72.
• On Wednesday, June 11th, John Paulson purchased 1,029,098 shares of Bausch Health Companies stock. The stock was acquired at an average price of $5.24 per share, for a total transaction of $5,392,473.52.
• On Tuesday, June 10th, John Paulson acquired 754,134 shares of Bausch Health Companies stock. The stock was bought at an average cost of $5.05 per share, for a total transaction of $3,808,376.70.

Bausch Health Companies Stock Down 3.0%

Shares of BHC stock traded down $0.18 during trading hours on Tuesday, reaching $5.73. The company's stock had a trading volume of 2,208,893 shares, compared to its average volume of 2,620,226. Bausch Health Companies Inc. has a fifty-two week low of $3.96 and a fifty-two week high of $9.85. The firm's 50 day simple moving average is $4.87 and its 200-day simple moving average is $6.39. The company has a market capitalization of $2.12 billion, a price-to-earnings ratio of -47.76, a PEG ratio of 0.37 and a beta of 0.28.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in BHC. SBI Securities Co. Ltd. increased its position in Bausch Health Companies by 244.2% during the 1st quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock worth $27,000 after purchasing an additional 3,001 shares in the last quarter. Cary Street Partners Financial LLC acquired a new position in shares of Bausch Health Companies in the 1st quarter worth approximately $27,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Bausch Health Companies in the 1st quarter valued at $27,000. Mountain Hill Investment Partners Corp. bought a new stake in shares of Bausch Health Companies in the 4th quarter valued at $56,000. Finally, Wealthquest Corp acquired a new stake in shares of Bausch Health Companies during the first quarter worth $58,000. Institutional investors own 78.65% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Wall Street Zen lowered shares of Bausch Health Companies from a "buy" rating to a "hold" rating in a research note on Saturday, May 10th. Royal Bank of Canada lifted their target price on Bausch Health Companies from $8.50 to $10.00 and gave the stock a "sector perform" rating in a report on Friday, May 2nd. One research analyst has rated the stock with a sell rating and seven have issued a hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $7.42.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.